ANDA 77097, held by Natco Pharma. Levofloxacin.
As of Nov 16, 2026, ANDA 77097 (Levofloxacin), held by Natco Pharma, was first approved by FDA on Jun 20, 2011, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 20, 2011 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levofloxacin750MG · tablet;oral | Levofloxacin | Discontinued |
| Sep 20, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 10, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| May 3, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 26, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 26, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 26, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 19, 2014 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 28, 2012 | Supplement 2Labeling | Approved | None posted |
| Oct 21, 2011 | Supplement 1Labeling | Approved | None posted |
| Jun 20, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters